The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.
Michael Friedlander
No relevant relationships to disclose
Katrin Marie Sjoquist
No relevant relationships to disclose
Dirkje Willemien Sommeijer
No relevant relationships to disclose
Lisa Bailey
No relevant relationships to disclose
Julie Martyn
No relevant relationships to disclose
Kim Gillies
No relevant relationships to disclose
Linda R. Mileshkin
No relevant relationships to disclose
Rachel O'Connel
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Michelle Margaret Vaughan
No relevant relationships to disclose
Penny Blomfield
No relevant relationships to disclose
Philip James Beale
No relevant relationships to disclose
Michael Quinn
No relevant relationships to disclose
Martin R. Stockler
No relevant relationships to disclose
Janine Margaret Lombard
No relevant relationships to disclose
Alison Maree Hadley
No relevant relationships to disclose
Frederic Amant
No relevant relationships to disclose
Richard J Edmondson
No relevant relationships to disclose